The DOI matches its Crossref record; 35 of the 37 references it cites were found in a registry or an index.
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans
Open accessAbstract
OBJECTIVE: Glucagon-like peptide (GLP)-1 lowers postprandial glycemia primarily through inhibition of gastric emptying. We addressed whether the GLP-1–induced deceleration of gastric emptying is subject to rapid tachyphylaxis and if so, how this would alter postprandial glucose control. RESEARCH DESIGN AND METHODS: Nine healthy volunteers (25 ± 4 years old, BMI: 24.6 ± 4.7 kg/m2) were examined with intravenous infusion of GLP-1 (0.8 pmol · kg−1 . min−1) or placebo over 8.5 h. Two liquid mixed meals were administered at a 4-h interval. Gastric emptying was determined, and blood samples were drawn frequently. RESULTS: GLP-1 decelerated gastric emptying significantly more after the first meal compared with the second meal (P = 0.01). This was associated with reductions in pancreatic polypeptide levels (marker of vagal activation) after the first but not the second meal (P < 0.05). With GLP-1, glucose concentrations declined after the first meal but increased after the second meal (P < 0.05). The GLP-1–induced reductions in postprandial insulin and C-peptide levels were stronger during the first meal course (P < 0.05). Likewise, glucagon levels were lowered by GLP-1 after the first meal but increased after the second test meal (P < 0.05). CONCLUSIONS: The GLP-1–induced delay in gastric emptying is subject to rapid tachyphylaxis at the level of vagal nervous activation. As a consequence, postprandial glucose control by GLP-1 is attenuated after its chronic administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Furthermore, GLP-1 can slow down gastric emptying by activating the vagus nerve, a part of the autonomic nervous system crucial for regulating the activities of the gastrointestinal tract.268”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [268]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 can slow down gastric emptying through its effects on smooth muscles and the nervous system in the gastrointestinal tract.264,268”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [268]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data also suggest that there is tachyphylaxis with prolonged use of GLP‐1 RAs [29, 60]”
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The magnitude of effect on GE, unlike the effects on glycaemic control or appetite, is attenuated with prolonged GLP-1 exposure.[2][3][4]”
From The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists (2020) · cites this paper as [3]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Native GIP mimicking postprandial GIP blood levels and GIPRAs did not reveal any relevant effects on GE. 3,[13][14][15]”
From The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists (2020) · cites this paper as [3]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“Although the glucose-lowering effect of GLP-1 in the fasting state is primarily mediated by its glucose-dependent augmentation of insulin secretion and inhibition of glucagon release (4,5), the key mechanism driving the postprandial normalization of glycemia by GLP-1 is a marked deceleration of gastric emptying leadin…”
BackgroundSelf-citationGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919 · cited 1×
“determined in ethanol-extracted plasma as previously described (15,18), using antiserum 89 390 for the measurement of intact GLP-1 [7–36 amide] plus cleavage products.”
MethodSelf-citationNauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817 · cited 2×
“fusion rate was based on previous studies (5,14) and was selected to increase”
BackgroundMethodSelf-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · cited 1×
“A deceleration of gastric emptying by GLP-1 has been demonstrated in patients with type 2 diabetes and healthy individuals (5,8,14).”
BackgroundSelf-citationMitrakou, A., Kelley, D., Mokan, M., Veneman, T., Pangburn, T., Reilly, J., & Gerich, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201023260104 · Cited by 595 · cited 1×
“This is in contrast with previous studies showing a significant decline in glucagon levels after intravenous or oral glucose ingestion (31,32).”
ResultEnhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Nauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506 · cited 3×
“Given the importance of GIP as a physiologic incretin hormone (15,34), this might theoretically impair postprandial insulin responses and thus worsen glucose control.”
BackgroundMethodSelf-citationWillms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
Self-citationMiyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · cited 1×
“Given the importance of GIP as a physiologic incretin hormone (15,34), this might theoretically impair postprandial insulin responses and thus worsen glucose control.”
BackgroundExplaining the Phenomenon of Nitrate Tolerance
Münzel, T., Daiber, A., & Mülsch, A. (2005) · Circulation Research · doi:10.1161/01.res.0000184694.03262.6d · Cited by 424 · cited 1×
“In analogy, the development of tachyphylaxis is well known to alter the actions of nitrates or catecholamines during constant pharmacologic exposure (11,12).”
Mechanisms of Hypoglycemia-Associated Autonomic Failure and Its Component Syndromes in Diabetes
Cryer, P. E. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3592 · Cited by 401
Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
Vagal, Cholinergic Regulation of Pancreatic Polypeptide Secretion
Schwartz, T. W., Holst, J. J., Fahrenkrug, J., Jensen, S. L., Nielsen, O. V., Rehfeld, J. F., de Muckadell, O. B. S., & Stadil, F. (1978) · Journal of Clinical Investigation · doi:10.1172/jci108992 · Cited by 386 · cited 1×
“Plasma pancreatic polypeptide (PP) was determined by RIA as described (21).”
MethodSelf-citationMeier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369 · cited 3×
“fusion rate was based on previous studies (5,14) and was selected to increase”
BackgroundMethodSelf-citationGlucagon physiology and pathophysiology in the light of new advances
Unger, R. H. (1985) · Diabetologia · doi:10.1007/bf00281991 · Cited by 361 · cited 1×
“This apparent discrepancy is most likely due to the high amino acid content of the test meal, which is known to stimulate rather than suppress glucagon secretion (33).”
BackgroundNew clinical method for measuring the rate of gastric emptying: the double sampling test meal.
George, J. D. (1968) · Gut · doi:10.1136/gut.9.2.237 · Cited by 354 · cited 1×
“Gastric emptying was measured as described (10) using a double-sampling dye dilution technique using phenol red (Merck AG, Darmstadt, Germany) according to George (16), with modifications introduced to reduce measurement error by Hurwitz (17).”
MethodMeier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314 · cited 1×
“In addition, GIP has also been shown to augment glucagon secretion in healthy humans (35).”
BackgroundSelf-citationGlucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
Self-citationEffect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261
Self-citationLittle, T. J., Pilichiewicz, A. N., Russo, A., Phillips, L., Jones, K. L., Nauck, M. A., Wishart, J., Horowitz, M., & Feinle-Bisset, C. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2220 · Cited by 212
Self-citationWettergren, A., Wøjdemann, M., & Holst, J. J. (1998) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1998.275.5.g984 · Cited by 197 · cited 2×
“The hypothesis of vagal nervous tachyphylaxis is further supported by the plasma concentrations of PP, which are thought to mirror the systemic level of vagal nervous activation (10,28).”
BackgroundSelf-citationHolst, J. J. (1982) · Biochemical Journal · doi:10.1042/bj2070381 · Cited by 176 · cited 1×
“Pancreatic glucagon was assayed in ethanol-extracted plasma using antibody 4305 (19).”
MethodSelf-citationLarsen, J., Hylleberg, B., Ng, K., & Damsbo, P. (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1416 · Cited by 171 · cited 1×
“However, when GLP-1 was administered intravenously over a period of 7 days in patients with type 2 diabetes, postprandial glucose concentrations declined after serving the first meal, whereas an increment in postprandial glucose levels was observed after the subsequent meal courses (13).”
BackgroundKrarup, T., Madsbad, S., Moody, A. J., Regeur, L., FABER, O. K., Holst, J. J., & Sestoft, L. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-56-6-1306 · Cited by 150 · cited 1×
“Plasma gastric inhibitory polypeptide (GIP) was determined by RIA using antiserum R 65 as previously described (20).”
MethodSelf-citationMeier, J. J., Kemmeries, G., Holst, J. J., & Nauck, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2212 · Cited by 146 · cited 8×
“Gastric emptying was measured as described (10) using a double-sampling dye dilution technique using phenol red (Merck AG, Darmstadt, Germany) according to George (16), with modifications introduced to reduce measurement error by Hurwitz (17).”
BackgroundMethodResultInfluentialSelf-citationTreatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors
Holst, J. J. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/eoed.9.1.155.32952 · Cited by 116
Self-citationMeier, J. J., Deacon, C. F., Schmidt, W. E., Holst, J. J., & Nauck, M. A. (2007) · Diabetologia · doi:10.1007/s00125-007-0598-z · Cited by 102 · cited 1×
“This is in contrast with previous studies showing a significant decline in glucagon levels after intravenous or oral glucose ingestion (31,32).”
ResultSelf-citationBaggio, L. L., Kim, J., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s205 · Cited by 95 · cited 1×
“For GLP-1, chronic exposure to a receptor antagonist in mice in vivo did not result in a significant receptor downregulation or attenuation of its glucoregulatory effects (23), thereby rendering this explanation less likely.”
BackgroundLipolytic catecholamine resistance due to decreased beta 2-adrenoceptor expression in fat cells.
Lönnqvist, F., Wahrenberg, H., Hellström, L., Reynisdottir, S., & Arner, P. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116103 · Cited by 81 · cited 1×
“In analogy, the development of tachyphylaxis is well known to alter the actions of nitrates or catecholamines during constant pharmacologic exposure (11,12).”
BackgroundTaylor, D. R., Sears, M. R., & Cockcroft, D. W. (1996) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70465-x · Cited by 70 · cited 1×
“Furthermore, chronic adaptation of the autonomous nervous system is a well-recognized principle, which is also responsible for many other phenomena, such as hypoglycemia unawareness (25), tolerance to b-adrenergic agonists (26), and opioid tolerance (27).”
BackgroundPeripheral versus central cardiorespiratory effects of morphine
Willette, R. N., & Sapru, H. N. (1982) · Neuropharmacology · doi:10.1016/0028-3908(82)90116-2 · Cited by 64 · cited 1×
“Furthermore, chronic adaptation of the autonomous nervous system is a well-recognized principle, which is also responsible for many other phenomena, such as hypoglycemia unawareness (25), tolerance to b-adrenergic agonists (26), and opioid tolerance (27).”
BackgroundTseng, C., Boylan, M. O., Jarboe, L. A., Usdin, T. B., & Wolfe, M. M. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.270.4.e661 · Cited by 56 · cited 13×
“GIP plasma concentrations increased by approximately fourfold after the test meals during placebo administration (Fig.”
BackgroundInfluentialMeasuring gastric volume by dye dilution.
Hurwitz, A. (1981) · Gut · doi:10.1136/gut.22.2.85 · Cited by 32 · cited 1×
“Gastric emptying was measured as described (10) using a double-sampling dye dilution technique using phenol red (Merck AG, Darmstadt, Germany) according to George (16), with modifications introduced to reduce measurement error by Hurwitz (17).”
Method
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“GLP-1 Actions in the Gastrointestinal Tract and Liver GLP-1R agonists inhibit gastric and small bowel motility, although the precise neuronal circuits responsible for these actions remain unclear, and the inhibition is subject to rapid tachyphylaxis and wanes with sustained GLP-1R activation (Nauck et al., 2011).”
BackgroundGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“In healthy human volunteers, intravenous GLP-1 decelerates gastric emptying after the first meal to a greater extent than after a second meal, indicating that GLP-1 inhibition of gastric emptying undergoes rapid desensitization [803].”
BackgroundSelf-citationGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Self-citationGlucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“268 When activated, the vagus nerve can reduce the contraction of the stomach, thereby slowing down food emptying.”
BackgroundThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Metadata
- Authors
- Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J.
- Affiliations
- Diabeteszentrum Bad Lauterberg (DE)
- Conservative Emergency Room, Klinikum Krefeld, Krefeld, Germany
- University of Copenhagen (DK)
- St. Josef-Hospital (DE)
- Corresponding author
- Nauck, Michael A.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-04-23
- Volume
- 60
- Issue
- 5
- Pages
- 1561-1565
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3292331
- OpenAlex
- W2163229244
- Cited by
- 392
- References
- 37
- Citations by year
- 2026: 35 · 2025: 32 · 2024: 38 · 2023: 23 · 2022: 18 · 2021: 22 · 2020: 21 · 2019: 23 · 2018: 20 · 2017: 17 · 2016: 24 · 2015: 26 · 2014: 33 · 2013: 42 · 2012: 11
- FWCI
- 24.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon-like peptide-1, tachyphylaxis, gastric emptying, postprandial glucose control, vagal activation, pancreatic polypeptide, insulin secretion, glucagon, C-peptide, mixed meal
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Gastric Emptying, Glucagon, Humans, Male, Tachyphylaxis, Postprandial Period, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.